Hematopoietic stem cell transplantation sales will strengthen through 2036, anchored by allogeneic transplants at 57.3% of the transplant type segment in 2026. Acute Myeloid Leukemia leads the application segment with a 38.5% share. The market is projected to reach USD 8.8 billion in 2026 and USD 18.61 billion by 2036.